trend justifi multipl
report much better expect result post
organ growth repres beat vs expect guidanc
put beat context figur compar perform
last quarter rel peer perkinelm elev level growth posit
break below-p rel trend compani post sinc begin
crux rel underweight rate perkinelm
note instrument sale primari driver upsid would like
see continu improv call new trend vs quarterli lumpi
remain somewhat skeptic given beat larger everi life
scienc tool peer post quarter broader base across recur
revenu categori addit worth point
favor comp quarter organ due malwar attack
said manag recent action acceler growth clearli start make
differ notic last four quarter quarterli
result broad-bas across end market geographi manag
note impact global account team custom
euroimmun acquisit pay post double-digit growth quarter
final made progress new growth opportun diagnost
across genet test nipt vanadi think could interest
get growth profil right key justifi valuat
trade premium peer ebitda despit mix track record
quarterli growth figur compani guid hsd long-term organ
revenu growth op margin
obvious link definit encourag quarter remain
cautiou whether inflect point justifi valuat reiter
rel underweight rate rais price
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
underweight compel
portfolio nich product across environment
human health long-term outlook
organ growth margin improv
compel believ share
range-bound near term get better
visibl emerg market revenu
opportun china nucleic acid test
newborn screen drive upsid
ebitda forecast upsid ebitda
million yield upsid case
emerg market fx remain pressur drive
downsid estim
downsid ebitda million yield downsid
case
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
report much better expect result post organ
growth repres beat vs expect guidanc put beat
context figur compar perform last quarter
rel peer perkinelm elev level growth posit break below-
peer rel trend compani post sinc begin
crux rel underweight rate note instrument sale
primari driver upsid would like see continu improv call
new trend vs quarterli lumpi remain somewhat skeptic given
beat larger everi life scienc tool peer post quarter
broader base across recur revenu categori addit worth point
favor comp quarter organ due
malwar attack said manag recent action acceler growth
clearli start make differ notic last four
quarter quarterli result broad-bas across end market geographi
manag note impact global account team custom
euroimmun acquisit pay post double-digit growth quarter final
made progress new growth opportun diagnost across
genet test nipt vanadi think could interest
get growth profil right key justifi valuat
trade premium peer ebitda despit mix track record
quarterli growth figur compani guid hsd long-term organ revenu
growth op margin obvious
link definit encourag quarter remain cautiou whether
inflect point justifi valuat reiter rel underweight rate
rais price price target repres
ebitda forecast million prior price target repres prior
ebitda forecast million
note agil post earn yet
rais organ growth ep guidanc reflect better
organ trend quarter full-year revenu expect billion
million midpoint previou guidanc repres increas y/i
revenu guidanc assum million million previous tailwind
fx million contribut million euroimmun
euroimmun acquisit expect provid tailwind around
impli guid organ growth previou
guidanc organ growth guidanc assum organ growth diagnost
da rais ep guidanc rais
attribut beat quarter due reduct tax rate
expect increment headwind fx compani continu
anticip margin expans tax rate expect lower
second consecut quarter previous
compani expect revenu million repres organ growth mid-teen
contribut euroimmun impact fx ep anticip
revenu improv y/i million emb underli
organ growth roughli tailwind euroimmun acquisit
tailwind fx revenu came ahead expect due better organ growth
off-set lower expect contribut fx acquisit euroimmun
import note acquisit contribut euroimmun line
compani guidanc organ growth result diagnost segment came
expect versu model da also outperform
versu drove organ growth upsid compani post organ
growth end market geographi remain optimist around
new product launch cite dollar contribut
guidanc guidanc y/i ebit barclay inc
revenu organ growth
revenu growth solid compani busi segment
diagnost segment revenu revenu grew organ
organ period growth broad base high-singl digit growth
reproduct health double-digit growth genom immunodiagnost
euroimmun acquisit ad revenu growth million
broad-bas strength across geographi describ observ four
close acquisit euroimmun decemb expand
compani presenc autoimmun allergi diagnost model organ
growth diagnost
discoveri analyt solut revenu revenu grew
organ quarter embed growth rate quarter dd growth
life scienc biopharma academ govern hsd growth appli
food environment industri specif within appli note
industri acceler hsd growth lsd declin
manag caution growth end market lumpi strength
biopharma benefit continu success onesourc better trend
drug discoveri product busi execut new product provid
tailwind growth model organ growth da
euroimmun acquisit appear good start post growth mid-
teen start manag lower full-year outlook revenu
though appear lower forecast fx driven remind
complet major acquisit euroimmun
decemb
euroimmun global manufactur diagnost workflow focu
autoimmun test grow presenc infecti diseas allergi test
euroimmun acquisit push mix faster grow market
addit top-lin growth one critiqu thesi
compani structur lower growth profil peer given lack
biopharma product asset meaning industri presenc take advantag
recent improv end market euroimmun gener around million
revenu increas compound-annual-growth-rate past year manag note
expect growth low-to-mid teen compani doesnt want
necessarili constrain level growth combin expand reach
autoimmun allergi diagnost market offer new infecti diseas
capabl custom china earli integr us gone well number
placement larg refer lab well anticip fda approv new
assay
year overal euroimmun growth broad-bas
geograph term test area effort increas manufactur
china euroimmun close open larg facil tianjin assum recent growth
rate hold euroimmun could add pro-forma top-lin growth
birth rate global headwind newborn screen
busi menu expans higher test util drive growth
compani approxim global market share newborn screen
first trimest prenat risk assess strong brand broad global channel
compani expect high single-digit growth newborn screen driven
three factor birth rate penetr screen number test
perform per babi market outsid us western europ repres
signific opportun recent strength busi driven menu
expans china enabl new mass spectrometri technolog
allow test per sampl overal screen penetr roughli china
averag util test per newborn util ms techniqu lower
roughli compani also see immens opportun india
babi screen shown chart approxim million
birth year global perkinelm estim new babi screen
market test perform per child
leader newborn screen particularli sensit chang
global birth rate follow broad decreas birth appear trend
revers cdc report increas addit
birth declin europ though increas china due end
one-child polici earn call provid commentari
china newborn screen busi continu impact msd hsd
birth rate declin across region despit birth rate headwind expand test
menu increas util enabl busi grow go forward
compani see signific opportun benefit increas menu usag china
screen util per babi remain low emerg market countri
util per babi roughli test increas
notabl effect birth rate would repres risk compani
millionsnorth americawestern europechinarest worldtotalnumb per barclay inc
y/i growth birth rate region
proxi birth rate note deliveri weak recent
turn posit said growth remain neg
stack basi way track newborn screen trend
track hca quarterli commentari deliveri compar annual birth rate
 report lag hca commentari give us real-tim view
biopharma increas double-digit quarter driven strength
onesourc drug discoveri product continu favor exposur peer
revenu grew organ onesourc compani servic offer
continu key growth driver onesourc lab servic offer continu
benefit outsourc trend biopharma major area focu growth
second consecut quarter biopharma product busi
area strength compani benefit better execut
contribut new product compani biopharma tool predominantli
biopharma mix compani
use discoveri front end research activ biopharma sponsor unlik
peer lack major presenc liquid chromatographi led lower
note alloc servic revenu research/product total
end market commentari solid quarter end market
geographi grow organ biopharma grew double-digit driven
broad strength across compani product servic onesourc busi
addit life scienc academ govern end market increas mid
single-digit note food end market grew mid single-
digit quarter environment end market grew double-digit
industri end market return high single-digit growth rebound follow low
single-digit declin diagnost end market post organ growth
broad strength across reproduct health genom immunodiagnost
geograph compani report double-digit organ growth asia europ
high-singl digit growth america emerg market grew double-digit
driven strength china dd growth india look continu
expand reach india recent tulip diagnost acquisit compani
enthusiast leverag tulip platform introduc legaci
euroimmun product market
perkinelm geograph divers rev
perkinelm revenu breakdown end market
gross margin prior year period adjust
fx compani note gross margin would expand fx
neutral basi outsid fx gross margin aid acquisit euroimmun
product improv core expans expect
gross margin improv
perkinelm gross margin ebitda margin
sg ex-stock comp expens increas y/i repres
revenu sg increas primarili driven increment expens form
euroimmun acquisit expens total sale y/i
increas invest vanadi well impact euroimmun
perkinelm adjust sg trend
report adjust ebit margin y/i
margin posit impact due acquisit euroimmun fx
headwind rel compani expect quarter margin
improv da segment y/i margin diagnost busi
continu impact season euroimmun y/i
compani anticip margin improv y/i addit perkinelm
continu target oper margin
perkinelm ebit margin annual growth
non-gaap ep increas y/i estim ep
beat driven stronger expect organ growth partial off-set unfavor
fx given beat manag rais full year non-gaap ep guidanc
non-gaap ep growth
cffo million quarter capital-expenditure million repres
revenu million quarter million
expect primarili due work capit drag anticip
compani repurchas share quarter follow divestitur
medic imag busi subsequ tulip euroimmun acquisit perkin
elmer cash balanc million
perkinelm use oper million
 mm except ep reportedincom growth profit ebitda ebit debt pre-tax pre-tax tax net net researchprior yearprior quarter barclay inc
estestestestestestestestestestincom statement growth growth growth growth growth growth growth y/i growth y/i organ adj growth product product revenu inc revenu inc servic servic gross gross margin inc gross margin inc growth growth base ebitda growth acquir oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax net net growth dilut adjust ep continu opsbas adj adj net barclay inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
